OSUR - OraSure Technologies, Inc.
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 12.02 |
| Open | 12.18 |
| Bid | 12.59 x 800 |
| Ask | 12.66 x 2200 |
| Day's Range | 12.16 - 12.94 |
| 52 Week Range | 5.23 - 18.27 |
| Volume | 1,653,168 |
| Avg. Volume | 1,658,745 |
| Market Cap | 899.377M |
| Beta (5Y Monthly) | 0.47 |
| PE Ratio (TTM) | 63.10 |
| EPS (TTM) | 0.20 |
| Earnings Date | Aug 04, 2020 - Aug 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.67 |
- GlobeNewswire
Diversigen, Inc. and Alimentiv Inc. Announce Collaboration Agreement for Ulcerative Colitis Research Study
Diversigen, Inc., a subsidiary of OraSure Technologies Inc. (OSUR), and Alimentiv Inc. (formerly Robarts Clinical Trials) today announced they have signed a collaboration agreement for a research study on patients with Acute Severe Ulcerative Colitis (ASUC). The study, titled: “Pharmacokinetics of Infliximab and Tumor Necrosis Factor Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis (PROTOS Study),” is designed to provide new insights into the molecular determinants of response to infliximab (IFX) in patients with ASUC. ASUC is the most aggressive presentation of ulcerative colitis (UC), and occurs in 15 percent of adults and children with UC.
- Insider Monkey
Hedge Funds Warming Up To OraSure Technologies, Inc. (OSUR)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
- GlobeNewswire
OraSure’s DNA Genotek Subsidiary Unveils First In-Home Self-Collection Device for Metabolomics
OraSure Technologies, Inc. (OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services is introducing the first and only commercially available device for in-home, self-collection of fecal samples for metabolomics. A product of OraSure’s DNA Genotek subsidiary, the OMNImet™·GUT (ME-200) augments the Company’s portfolio of multiomic sample collection products. “Advances in the prediction, detection, understanding, and monitoring of human diseases have increased the use of metabolomics technologies,” said Kathleen Weber, Executive Vice President, Business Unit Leader, Molecular Solutions at DNA Genotek.
- PR Newswire
Metabolon, Inc. and DNA Genotek Collaborate on First Ambient-Temperature Microbiome Sampling Solution for Metabolomics
Metabolon, Inc., the global leader in metabolomics, and DNA Genotek, a subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), have collaborated to bring OMNImet™·GUT, the first device for in-home collection and ambient-temperature storage and shipping of fecal samples for metabolomics, to the research market.
- Thomson Reuters StreetEvents
Edited Transcript of OSUR.OQ earnings conference call or presentation 6-May-20 9:00pm GMT
Q1 2020 OraSure Technologies Inc Earnings Call
- GlobeNewswire
OraSure Technologies Receives BARDA Funding for Coronavirus Antibody ELISA Using Oral Fluid Samples
OraSure Technologies, Inc. (OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laboratory and analytical services, today announced it has been awarded a $629,217 contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to develop an Enzyme-Linked Immunosorbent Assay (ELISA) for the detection of human anti-SARS-CoV-2 antibodies in oral fluid specimens. Currently, there are no oral fluid-based COVID antibody tests available with automated assays. This support from BARDA will help OraSure complete development and file for FDA Emergency Use Authorization (EUA), which would allow the laboratory-based microplate antibody test for oral fluid samples to enter into the U.S. market.
- GlobeNewswire
OraSure’s Oragene®•Dx included in EUA allowing at-home saliva collection for use with Phosphorus SARS-CoV-2 test
OTTAWA, June 08, 2020 -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and.
- GlobeNewswire
OraSure Technologies, Inc. Announces Exercise of Option to Purchase Additional Shares of Common Stock
In total, 9,200,000 shares of common stock of the Company are being sold in the offering. With the exercise by the underwriters of their option to purchase such additional shares, after the underwriting discount and estimated offering expenses, OraSure expects to receive net proceeds of approximately $94.9 million. J.P. Morgan Securities LLC, Citigroup and Evercore Group L.L.C. are acting as joint book‑running managers of the offering and as representatives of the underwriters.
- GlobeNewswire
OraSure Technologies, Inc. Prices Underwritten Offering of Common Stock
After the underwriting discount and estimated offering expenses, OraSure expects to receive net proceeds of approximately $82.48 million. In addition, OraSure has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 of shares of its common stock. J.P. Morgan Securities LLC, Citigroup and Evercore Group L.L.C. are acting as joint book-running managers of the offering and as representatives of the underwriters.
- GlobeNewswire
OraSure Technologies, Inc. Announces Proposed Public Offering of Common Stock
J.P. Morgan Securities LLC, Citigroup Global Markets Inc. and Evercore Group L.L.C. are acting as joint book running managers of the offering and as representatives of the underwriters. UBS Investment Bank and Raymond James & Associates, Inc. are acting as co-managers. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock offered in the public offering.
- GlobeNewswire
OraSure Technologies, Inc. Announces Purchase of UrSure, Inc.
OraSure Technologies, Inc. (OSUR), a leader in point of care diagnostic tests and specimen collection and stabilization devices, and microbiome laboratory and analytical services, today announced that it has entered into a definitive agreement to acquire privately owned UrSure, Inc. (“UrSure”) for cash. Based in Boston, UrSure is developing and commercializing products that measure adherence to HIV medications including pre-exposure prophylaxis or PrEP, the daily medication to prevent HIV. PrEP has been shown to be 99 percent effective at preventing HIV infection when taken daily, adding another tool to help ensure that patients stay healthy.
- GlobeNewswire
OraSure Technologies Appoints Lelio Marmora to Board of Directors
OraSure Technologies, Inc. (OSUR), a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced the appointment of Lelio Marmora as a member of the Company’s Board of Directors effective June 1, 2020. Mr. Marmora, the former executive director of Unitaid, will serve as a Class III Director with an initial term expiring at the Company’s 2021 Annual Meeting of Stockholders.
- GlobeNewswire
OraSure Technologies to Present at the Jefferies 2020 Healthcare Conference
BETHLEHEM, Pa., May 26, 2020 -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory.
- GlobeNewswire
OraSure’s OMNIgene®·ORAL Kit Included in EUA Granted to P23 Labs for At-Home Collection of Saliva Samples for SARS-CoV-2 Test
OTTAWA, May 22, 2020 -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and.
- GlobeNewswire
Diversigen Inc. Selected by Nom Nom™ as the Preferred Provider for Metagenomics and Microbiome Sequencing and Analysis Services
Diversigen, Inc., a subsidiary of OraSure Technologies Inc. (OSUR), and Nom Nom™, a direct-to-consumer pet health brand, today announced that Nom Nom has selected Diversigen as their preferred provider for metagenomics and microbiome sequencing and analysis services. Diversigen will also serve as Nom Nom’s central lab for the generation of high quality microbiome data.
- GlobeNewswire
OraSure Technologies to Present at the UBS Virtual Global Healthcare Conference
BETHLEHEM, Pa., May 15, 2020 -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Dr..
- GlobeNewswire
OraSure Technologies to Hold Virtual Annual Meeting of Stockholders on May 19, 2020
BETHLEHEM, Pa., May 14, 2020 -- OraSure Technologies, Inc. (NASDAQ: OSUR), announced that its 2020 Annual Meeting of Stockholders will be a completely virtual meeting,.
- GlobeNewswire
OraSure Technologies, Inc. Consolidates Microbiome Services Subsidiaries
OraSure Technologies, Inc. (OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its Diversigen and CoreBiome subsidiaries have combined their microbiome service offerings under the Diversigen name. The rebrand highlights the combined companies’ unparalleled scientific bench strength, state-of-the-art laboratory, ability to translate data to insights and collective focus on quality and service. The unified Diversigen operation will continue to offer the science-driven, customized solutions for metagenomics sequencing, bioinformatics, and statistical analysis for the study of the microbiome for which CoreBiome and Diversigen are known.
- Motley Fool
OraSure Technologies (OSUR) Q1 2020 Earnings Call Transcript
With us today are Dr. Stephen Tang, president and chief executive officer; and Mr. Roberto Cuca, chief financial officer. Dr. Tang and Mr. Cuca will begin with opening statements, which will be followed with a question-and-answer session. Tang, you should note that this call may contain certain forward-looking statements, including statements with respect to revenues, expenses, profitability, earnings or loss per share and other financial performance, product development, performance, shipments and markets, business plans, regulatory filings and approvals, expectations and strategies.
- GlobeNewswire
OraSure Announces 2020 First Quarter Financial Results and Provides COVID-19 Update
BETHLEHEM, Pa., May 06, 2020 -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laboratory and.
- GlobeNewswire
OraSure Technologies Appoints Lisa Nibauer as Infectious Disease Business Unit Lead
OraSure Technologies, Inc. (OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that Lisa Nibauer has been appointed Executive Vice President, Business Unit Leader, Infectious Disease. Mr. Zezzo has agreed to work with Ms. Nibauer to ensure smooth and successful transition of duties, while maintaining his current pivotal role in OraSure’s COVID-19 activities.
- GlobeNewswire
DNA Genotek’s ORAcollect®·RNA kit included in EUA granted to Biocerna SARS-CoV-2 test
OTTAWA, May 04, 2020 -- DNA Genotek Inc., a leading provider of sample collection kits and end-to-end services and a wholly-owned subsidiary of OraSure Technologies, Inc..
- Simply Wall St.
Can You Imagine How Jubilant OraSure Technologies' (NASDAQ:OSUR) Shareholders Feel About Its 173% Share Price Gain?
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far...
- GlobeNewswire
OraSure Technologies Earnings Conference Call Invitation
2020 First Quarter Earnings Conference Call Wednesday, May 6, 2020, 5:00 p.m. ET BETHLEHEM, Pa., April 09, 2020 -- OraSure Technologies, Inc. (NASDAQ: OSUR) has.
- American City Business Journals
Lehigh Valley medical device company working on at-home COVID-19 test
The Bethlehem company received federal funding for the project from Biomedical Advanced Research and Development Authority.
